# Medicover account plan

> Medicover is a Stockholm-listed healthcare and diagnostics group in Central and Eastern Europe, with FY2025 revenue of €2,378.1m and 49,409 co-workers.

## At a glance

Medicover is a healthcare services and diagnostics group founded in 1995 and listed on Nasdaq Stockholm since 2017, operating clinics, hospitals, dental and fertility clinics, gyms, laboratories and blood-drawing points. Its primary markets are Poland, Germany and Romania, with Poland 52% of FY2025 revenue, and 79% of group revenue comes from private pay (employer-funded plans and fee-for-service). FY2025 revenue was €2,378.1m (+13.7%, organic 12.7%), EBITDA €371.0m (15.6% margin) and profit for the year €72.7m, with 49,409 co-workers. In August 2026 it agreed to sell its Indian hospitals to funds managed by KKR. Celox Holding AB holds 56.0% of the votes.

## Business units

- **Healthcare Services** (69% of FY2025 revenue (€1,650.2m)): Outpatient and inpatient care, dentistry, fertility, eye care, pharmacies, mental health and sports and wellness, sold as employer-funded plans, fee-for-service and public contracts; Poland is 70% of divisional revenue. In 2025 it ran 187 medical clinics, 41 hospitals, 110 dental clinics and 176 gyms, and EBITDA margin rose to 17.4%. Q3 2026 revenue was EUR 374.7 million (+6.0%), with sports and wellness the strongest contributor.
- **Diagnostic Services** (31% of FY2025 revenue (€754.9m)): Laboratory testing, genetic testing, CE-IVD kits and clinical trial services through 135 laboratories and 1,046 blood-drawing points in 15 countries, with brands such as Synevo and IMD Laboratory Berlin; Germany is 43% of divisional revenue. It ran 152.4 million tests in 2025 and integrated the SYNLAB businesses acquired in six countries. Q3 2026 revenue was EUR 203.8 million (+6.3%), with Germany and genetics softer.
- **Medicover Hospitals India** (€203.6m revenue (FY2025)): 23 hospitals with 4,728 beds in four Indian states, 66.9% owned at end-2025. Now reported as a discontinued operation: Medicover agreed on 6 August 2026 to sell it to funds managed by KKR, with closing expected in Q4 2026.

## Strategic priorities

- **2026-2028 financial targets**: Organic revenue above €3.25bn and adjusted organic EBITDA above €600m by 2028, leverage of 3.0x or less and a payout of up to 50%, unchanged until the India sale closes.
- **Refocus on three European markets**: Proceeds of approximately EUR 0.74bn from the India sale are to accelerate strategy execution in Poland, Germany and Romania.
- **Expand the service offering**: Grow speciality care (hospitals, dental, mental health, orthopaedics, sports and wellness) and advanced diagnostics; in Poland Medicover has consolidated only about 5% of the dental market and plans more hospitals.
- **Operational excellence**: Procurement savings, a hub-and-spoke laboratory network on a proprietary laboratory information system, higher capacity utilisation and technology to cut doctors' administrative work.
- **Digital differentiation**: Apps, telemedicine, digital triage and AI, including voice recognition and automated medical records, described as central to running and growing the business.
- **Selective M&A and consolidation**: 86 acquisitions since the 2017 IPO; the CEO expects further consolidation in Poland and Romania as competitors reliant on public funds struggle.

## Latest results

In Q3 2026 (continuing operations, India excluded), revenue rose 6.0% to EUR 570.8 million with organic growth of 8.0% and a 2.0% currency drag; EBIT grew 22.0% to EUR 49.3 million at an 8.6% margin, and net profit was EUR 24.8 million. It was the seventh consecutive quarter of year-on-year margin improvement. Over nine months, revenue was EUR 1,721.6 million (+6.4%, organic +8.5%). Leverage fell to 2.7x from 3.1x at end 2025, and a new EUR 450.0 million RCF was signed. Management flags near-term softness in public reimbursement, a German genetics reform from October 2026, and slower B2B membership.

## Investments and deals

- **SYNLAB businesses acquisition**: Completed in 2025 in Romania, Turkey, Cyprus, Slovenia, Croatia and North Macedonia: 30 laboratories, 100 blood-drawing points and over 600 professionals.
- **CityFit gym chain**: Acquired in 2025 in Poland: 26 clubs and nearly 130,000 active members; 16 new fitness facilities opened in 2026 so far, with openings set to accelerate.
- **Sale of Medicover Hospitals India**: A EUR 1.2 billion transaction with funds managed by KKR announced 6 August 2026; Medicover's 66.1% stake brings about EUR 740 million and should leave it debt-free.
- **Capex and network reshaping**: Capex in PP&E and intangibles was €158.1m in 2025; full-year 2026 capex is guided at 6-6.5% of revenue, and 118 facilities were closed while over 140 opened in twelve months.
- **Medicover Genetics MRD test**: A blood-based minimal residual disease test for lung cancer recurrence, launched in 2026, detects issues 7.4 months earlier than traditional methods.

## Challenges and risks

- **Public reimbursement cuts**: German laboratory reimbursement fell from 1 January 2025, a German genetics reform took effect in October 2026, and Romania brought caps and tariff cuts in public healthcare.
- **Medical workforce shortage**: Rated a High risk in the 2025 risk register; inflation-driven medical salary increases weigh on Polish inpatient margins.
- **Geopolitical and data risks**: Armed conflict (Ukraine) and data loss or breach are the other two risks rated High.
- **Slower B2B membership**: Members fell to 1,487K in Q3 2026 from 1,549K, mainly in Romania, after pricing decisions and slower employer hiring.

## What leadership says

> "maybe we kept our prices a little bit too high for a little bit too long, and we need to repurpose or make adjustments, which we've done." — John Stubbington, CEO, Q3 2026 earnings call (2026-11-04)

> "The Indian divestment brings us EUR 740 million, and we will focus that money on our core countries." — John Stubbington, CEO, Q3 2026 earnings call (2026-11-04)

> "First and foremost, you need scale in healthcare. That's why our number one strategic priority remains growth." — John Stubbington, CEO, Warsaw Business Journal interview (2025-08-25)

> "We've all seen doctors typing with one finger" — John Stubbington, CEO, Warsaw Business Journal interview, on efficiency (2025-08-25)


## Where a supplier can help

- **Clinical documentation and AI**: The efficiency priority of freeing doctors from administrative work, with voice recognition and automated medical records, opens room for clinical AI and documentation tools.
- **Laboratory automation**: Consolidation and automation are Medicover's answer to German reimbursement cuts, a fit for lab automation, LIS and logistics suppliers.
- **Fit-out for new gyms, clinics and hospitals**: Accelerated gym openings, planned Polish hospitals and over 140 new facilities in twelve months create demand for equipment, construction and facility services.
- **Post-acquisition integration**: The SYNLAB integration and expected further consolidation, funded by the India proceeds, call for integration, IT migration and procurement support.
- **Workforce and data security**: Workforce shortage and data breach risks, both rated High, point to recruiting, retention and cyber security offerings.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Medicover Annual Report 2025](https://storage.mfn.se/b05e68fa-9240-44a1-b79b-ef6943ec3a9c/medicover-annual-report-2025.pdf)

Annual report · 2026-03-30

- Medicover is a Stockholm-listed (Nasdaq Stockholm since 2017) healthcare and diagnostics group founded in 1995, operating in Central and Eastern Europe and India through two divisions: Healthcare Services (69% of revenue) and Diagnostic Services (31%).
- FY2025 revenue was €2,378.1m (+13.7%, organic growth 12.7%); EBITDA €371.0m (15.6% margin, up from 13.6%); operating profit €155.7m (€70.3m); profit for the year €72.7m (€14.6m); 49,409 co-workers.
- Revenue by country: Poland 52%, Germany 16%, Romania 13%, India 9%, Other 10%; 79% of group revenue comes from private pay, reflecting low reliance on public funding.
- 2023-2025 financial targets were exceeded (organic revenue €2.3bn vs >€2.2bn target; adjusted organic EBITDA €369m vs >€350m; leverage 3.1x vs ≤3.5x). New 2026-2028 targets: organic revenue >€3.25bn, adjusted organic EBITDA >€600m, leverage ≤3.0x, dividend payout up to 50%.
- 2025 brought the two largest acquisitions in Medicover's history: SYNLAB's businesses in Romania, Turkey, Cyprus, Slovenia, Croatia and North Macedonia (30 laboratories, 100 blood-drawing points) and the CityFit gym chain in Poland (26 locations in 17 cities).
- John Stubbington (with Medicover since 2010, previously leading Healthcare Services) became CEO on 1 May 2025, succeeding Fredrik Rågmark after 25 years; Anand Patel is CFO.
- Strategy: three core strategies (retain and grow the customer base, expand the service offering, pursue operational excellence) plus two supporting strategies (digital differentiation, selective M&A); 86 acquisitions since the 2017 IPO.
- Key risks rated High: armed conflict and geopolitical risk (Ukraine, increasing), data loss or breach, and medical workforce shortage; German laboratory reimbursement cuts from 1 January 2025 were managed through consolidation and automation.
- Medicover Genetics' ctDNA-based minimal residual disease (MRD) assay for lung cancer showed positive interim results in the DART study, with commercialisation planned for H2 2026.

### [Interim report July-September 2026](https://storage.mfn.se/20ac5744-f0cd-4c3f-8e6d-29d2f1b48938/interim-report-july-september-2026.pdf)

Interim report · 2026-11-04

- Q3 2026 (continuing operations, Indian hospitals now reported as discontinued): revenue EUR 570.8m (+6.0%, organic +8.0%, FX -2.0%); EBIT EUR 49.3m (+22.0%, margin 8.6% vs 7.5%); EBITDA EUR 99.3m (17.4% margin); net profit EUR 24.8m.
- Medicover agreed on 6 August to sell Medicover Hospitals India to funds managed by KKR; its 66.1% stake brings gross cash proceeds of approximately EUR 0.74bn, with closing expected in Q4 2026, to be used for strategy execution in Poland, Germany and Romania.
- Nine months 2026: revenue EUR 1,721.6m (+6.4%, organic +8.5%); EBIT EUR 145.0m (8.4% margin); EBITDA EUR 294.5m (17.1%).
- Healthcare Services Q3: revenue EUR 374.7m (+6.0%, organic +8.0%, of which price about 6.3pp), EBITDA margin 19.8%; 16 new fitness facilities opened in 2026; members 1,487K (1,549K), falling in Romania; over 4.1 million ongoing customer relationships.
- Diagnostic Services Q3: revenue EUR 203.8m (+6.3%, organic +8.5%), EBITDA margin 18.5%; 40.2 million tests (+5.3%); FFS is 74% of divisional revenue; Germany and genetics softer.
- A German genetics reimbursement reform effective October 2026 is expected to lower margin contribution; the CEO expects "continued softness in public reimbursement" near term.
- Leverage 2.7x (3.1x at end 2025); 118 facilities closed and over 140 opened in the last twelve months; 2026-2028 targets (organic revenue >EUR 3.25bn, adjusted organic EBITDA >EUR 600m, leverage ≤3.0x) unchanged until the India deal completes.

### [Medicover Q3 2026 earnings call transcript](https://stockanalysis.com/quote/sto/MCOV.B/transcripts/538770-q3-2026/)

Executive talk · John Stubbington, CEO · 2026-11-04

- CEO John Stubbington and CFO Anand Patel presented Q3 2026: 8% organic growth on continuing operations and a seventh consecutive quarter of year-on-year margin improvement; EBIT up 22%.
- The India hospital sale (transaction of EUR 1.2 billion, Medicover's 66.1% share about EUR 740 million) is a complete exit; Stubbington says the money will go to "our core countries" and Medicover should be debt-free after closing.
- Near-term headwinds flagged: public reimbursement changes, 118 closed locations, slower B2B membership (Romania), and a German genetics reform he calls "quite brutal" on face value, which "will hit us" but should be managed over about four quarters.
- Funded growth in Poland had relied on price; Stubbington admits "maybe we kept our prices a little bit too high for a little bit too long" and says the B2B pipeline is now stronger.
- Sports and wellness in Poland is accretive and growing faster than core Healthcare Services; openings will accelerate in Q4 and beyond, with Poland still behind Western Europe in gyms per head.
- Medicover launched its blood-based MRD test detecting lung cancer recurrence, which picks up issues 7.4 months earlier than traditional methods.
- With funds available and competitors squeezed by rates and government changes, he expects "further consolidation"; CFO guides full-year capex at 6-6.5% of revenue and leverage fell to 2.7x.

### [Medicover Q2 2026 earnings call transcript](https://stockanalysis.com/quote/sto/MCOV.B/transcripts/538768-q2-2026/)

Executive talk · John Stubbington, CEO · 2026-07-22

- Q2 2026 (before India was reclassified): revenue EUR 640.4 million, organic growth 11.8%, adjusted EBITDA EUR 109.2 million at a 17.1% margin, the sixth consecutive quarter of margin improvement; leverage 2.9x.
- India hospitals grew 23.1% in euros and 39.6% in local currency; Stubbington said the Indian IPO "still very much is an option" while the company evaluated inbound interest (KKR talks had been reported in June).
- Healthcare Services organic growth 12.2% (price 5.2%); funded business in Poland growing again; Romanian membership cut after "harsher decisions" on unprofitable contracts.
- Diagnostics organic growth 10.9% with margin up 110 basis points; synergies from the two 2025 acquisitions, "our largest in our history", are coming through.
- Romania's political instability brought caps and tariff cuts in public healthcare; Stubbington expects patients to switch to fee-for-service: "Usually that creates opportunity for us."
- On Polish government plans affecting doctors' pay and public procedures: "This is business as usual to us."
- CFO Anand Patel: EBIT EUR 51.2 million at an 8% margin, ROIC 13.6% (9.3%), capex about 6% of revenue for the year; 2028 targets still expected to be achieved.

### [Medicover's Scaling Strategy: Growth, Efficiency and Customer Satisfaction (WBJ interview with John Stubbington)](https://wbj.pl/medicovers-scaling--strategy-growth-efficiency--and-customer-satisfaction/post/147008)

Executive talk · John Stubbington, CEO · 2025-08-25

- Interview in the Warsaw Business Journal with John Stubbington shortly after he became CEO; he joined Medicover in 2010 after 17 years at Bupa to look after its insurance company with one employee.
- His side of the business grew from around €100 million to approximately €2.4-2.5 billion; Medicover has added roughly 700,000 square meters of care space and is approaching a million square meters.
- Three strategic priorities for the next decade: growth (scale lets Medicover specialise), efficiency (empowering customers, freeing doctors from administrative work) and satisfaction (around 600,000 surveys a year).
- Medicover is the largest dental provider in Poland but has consolidated only about 5% of a fragmented market; it both builds greenfield sites and acquires.
- Growth areas in Poland: gyms and fitness (smaller operators, no large chains left to buy) and hospitals (11 in Poland today, more planned through acquisitions or new builds).
- Government-funded work is a relatively small share; "The vast majority of what we do is private pay".

## Questions about Medicover

### What does Medicover do?

Medicover runs healthcare services (clinics, hospitals, dental, fertility, gyms) and diagnostic laboratories, mainly in Poland, Germany and Romania, funded mostly by private pay.

### What is Medicover's revenue?

FY2025 revenue was €2,378.1m, up 13.7%, with EBITDA of €371.0m. Q3 2026 revenue from continuing operations was EUR 570.8 million.

### How many employees does Medicover have?

49,409 co-workers at end of 2025.

### Who leads Medicover?

John Stubbington has been CEO since 1 May 2025, Anand Patel is CFO, and Fredrik Stenmo chairs the board.

### Why is Medicover selling its Indian hospitals?

The sale to funds managed by KKR brings about EUR 740 million for Medicover's 66.1% stake, to be focused on Poland, Germany and Romania.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
